DRUG IMCGP100-202 -A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator’s Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma

Project: Research project

Project Details

StatusFinished
Effective start/end date11/14/17 → 11/14/20

Funding

  • DrugDev Inc. (IMCGP100-202 // IMCGP100-202)
  • Immunocore Limited (IMCGP100-202 // IMCGP100-202)